SCHEMBL24571978

SCHEMBL24571978

OCc1cc2ccc(Cl)nc2n1CC1CC1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.38
CTSS P25774 1/20 0.38
CTSK P43235 1/20 0.38
CCR9 P51686 1/20 0.36
ROCK2 O75116 1/20 0.31
ROCK1 Q13464 1/20 0.31
ALOX5 P09917 1/20 0.31
PDE5A O76074 2/20 0.30
PDE4A P27815 2/20 0.30
PDE4B Q07343 2/20 0.30
PDE4C Q08493 2/20 0.30
PDE4D Q08499 2/20 0.30
PIM1 P11309 1/20 0.30
PIM3 Q86V86 1/20 0.30
PIM2 Q9P1W9 1/20 0.30
NOTUM Q6P988 1/20 0.30
RORA P35398 1/20 0.30
RORC P51449 1/20 0.30
RORB Q92753 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29641062 1.00 CTSL (0.38) CTSLCTSSCTSKCCR9ROCK2
SCHEMBL29942136 0.79 CCR9 (0.34) CTSLCTSSCTSKCCR9PDE5A
SCHEMBL23755703 0.79 CCR9 (0.34) CTSLCTSSCTSKCCR9PDE5A
SCHEMBL23777027 0.79 NOTUM (0.40) CTSLCTSSCTSKCCR9ALOX5
SCHEMBL26660758 0.79 CNR2 (0.38)
SCHEMBL31501882 0.79 CNR2 (0.38)
SCHEMBL29850694 0.78 CCR9 (0.56) CCR9ROCK2ROCK1NOTUM
SCHEMBL18940655 0.78 CCR9 (0.56) CCR9ROCK2ROCK1NOTUM
SCHEMBL28960943 0.77 CCR9 (0.41) CTSLCTSSCTSKCCR9ROCK2
SCHEMBL30122584 0.77 CCR9 (0.33) CTSLCTSSCTSKCCR9PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250346592-A1 HETEROCYCLIC PAD4 INHIBITORS CELGENE CORPORATION 2025-11-13 US disclosed
EP-4531849-A1 HETEROCYCLIC PAD4 INHIBITORS CELGENE CORPORATION (US) 2025-04-09 EP disclosed
WO-2023230609-A1 HETEROCYCLIC PAD4 INHIBITORS CELGENE CORPORATION (US) 2023-11-30 WO disclosed
WO-2023230609-A1 HETEROCYCLIC PAD4 INHIBITORS CELGENE CORPORATION (US) 2023-11-30 WO disclosed
WO-2022140390-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2022-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346592-A1 HETEROCYCLIC PAD4 INHIBITORS PADI4, PADI6, PADI2 CTSL 4243/4885CTSS 4137/4885CTSK 4092/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.